Use of rivaroxaban moderates the bleeding risk associated with oral anticoagulation plus antiplatelet treatment after percutaneous coronary intervention in patients with atrial fibrillation, indicate results of the phase III PIONEER AF-PCI trial.
Atrial fibrillation is associated with an increased risk of a wide range of adverse outcomes including death and cardiovascular and renal disease, results of a systematic review and meta-analysis involving more than 9 million individuals show.
A history of atrial fibrillation is associated with an increased risk of in-hospital bleeding, heart failure, cardiogenic shock and mortality among patients undergoing percutaneous coronary intervention, US study data show.
Only one-third of patients who achieve a stable international normalised ratio during 6 months of warfarin therapy will maintain that stability during the subsequent year’s treatment, US researchers report.
The benefits of apixaban 5 mg over warfarin are maintained in patients with atrial fibrillation who are of advanced age, have low body weight or elevated creatinine levels, analysis of ARISTOTLE data shows.
Reintervention and rehospitalisation rates are significantly lower with cryoballoon ablation than with radiofrequency current catheter ablation in patients with symptomatic paroxysmal atrial fibrillation, FIRE AND ICE study data show.
Black individuals with atrial fibrillation have markedly higher rates of stroke, heart failure, coronary heart disease and mortality than their White counterparts, data from the Atherosclerosis Risk in Communities study show.